MAP0005

MAP0005 is an investigational inhaled combination drug developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It consists of a single-particle formulation that combines budesonide, a corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist. The drug is delivered to the respiratory tract using MAP Pharmaceuticals' proprietary Tempo inhaler, which synchronizes drug discharge with the patient's breathing cycle for optimized delivery. The unique particle technology allows both active ingredients to be combined in a fixed ratio within one particle, aiming to improve dosing consistency and potentially enhance safety and efficacy compared to existing combination therapies. Clinical development reached Phase 2a trials but further direct investment was not planned by the developer; partnership opportunities were being explored[3][6][8].